Micha P. Krahl is Head of Quality Control of ABX advanced biochemical compounds GmbH based in Heinrich-Glaeser-Strasse 10 - 14. Radeberg, 01454. Germany. Previously worked at ABX advanced biochemical compounds GmbH as a Head of Quality Control (Acting). ABX advanced biochemical compounds GmbH is a Manufacturing, Pharmaceuticals company in Heinrich-Glaeser-Strasse 10 - 14. Radeberg, 01454. Germany with 79 employees.
Micha P. Krahl has 23 years of professional experience, with an average of 3 years per position throughout their career. Their recent employment history shows 0 changes in the past 3 years, with high job stability. they have Fortune 500 company experience.
Micha P. Krahl have a experience in top university. Micha P. Krahl holds a degree from Technische Universität Dresden, with 20 years since graduation. Their career include experience at a global enterprise.
ABX advanced biochemical compounds GmbH is founded in 1997, operates from its headquarter in Heinrich-Glaeser-Strasse 10 - 14. Radeberg, 01454. Germany. The company operates in the Manufacturing, Pharmaceuticals sector.
ABX advanced biochemical compounds GmbH specializes in Custom synthesis and manufacturing of precursors and peptides, GMP compliance, Hot lab for R&D, Stability studies, In-house sterility testing of radioactive pharmaceuticals, Production of aseptic excipients and sterile disposables, Authorization as a radiopharmaceutical drug producer, ASMFs (Active Substance Master Files), US-DMFs (Drug Master Files), Technical documents for reagent kits and cassettes, and offers services including Radiopharmaceuticals, Positron Emission Tomography (PET) tracers, and Single Photon Emission Computed Tomography (SPECT) precursors.
ABX advanced biochemical compounds GmbH has hired 1 new employees in the past 6 months..
Micha P. Krahl completed at Technische Universität Dresden (2003 - 2006) , at Technische Universität Dresden (Present) , etc
These email and Phone numbers are the most updated and verified contact information for Micha P. Krahl found in 2025.